Uphuculo olubalulekileyo kwiSifo esinzima kwi-Atopic Dermatitis

Kwiiveki ze-16, iipesenti ze-70 zezigulane ezine-atopic dermatitis ephakathi ukuya kwi-atopic (AD) efumana i-lebrikizumab edibene ne-standard-of-care topical corticosteroids (TCS) iphumelele ubuncinane i-75 yepesenti yokuphucula ubunzima besifo (EASI-75 *) uvavanyo lwe-ADhere, u-Eli Lilly kunye neNkampani (NYSE: LLY) ibhengezwe namhlanje kwiNkomfa ye-4 ye-Revolutionizing Atopic Dermatitis (RAD). I-Lebrikizumab, i-Inhibitor ye-IL-13 yophando, iphinde yabonisa ukuphuculwa kwe-itch, ukuphazamiseka kokulala, kunye nomgangatho wobomi xa idibene ne-TCS, xa kuthelekiswa ne-placebo kunye ne-TCS.

"Idatha ye-ADhere yanamhlanje, kunye neziphumo ezivela kwizifundo ze-Advocate monotherapy, zibonisa amandla okuba i-lebrikizumab yokunciphisa umthwalo wesifo kunye nokubonelela ngesiqabu kubantu abane-atopic dermatitis engalawulwayo xa isetyenziswe yodwa okanye idityaniswe nezihloko," utshilo u-Eric Simpson, MD, MCR. Unjingalwazi weDermatology kunye noMlawuli woPhando lweKlinikhi kwi-Oregon Health & Science University ePortland, kunye nomphandi oyintloko we-ADhere. "I-Lebrikizumab ijolise ngokukodwa kwindlela ye-IL-13, edlala indima ephambili kwesi sifo singapheliyo. Ezi ziphumo zomeleza ukuqonda kwethu i-lebrikizumab kwi-atopic dermatitis kwaye inceda ukuyiseka njengonyango olutsha olunokwenzeka.

I-Lebrikizumab yinveli, i-monoclonal antibody (mAb) ebophelela kwiprotheni ye-interleukin 13 (IL-13) ene-high affinity ukukhusela ngokukodwa ukubunjwa kwe-IL-13Rα1 / IL-4Rα (Uhlobo lwe-2 receptor) oluthintela ukubonakaliswa kwezantsi nge-IL. -13 pathway.1-5 IL-13 idlala indima ephambili kwi-Type 2 ukuvuvukala kwi-AD.6,7 Kwi-AD, i-IL-13 iphantsi kweempawu kunye neempawu ezibandakanya ukungasebenzi kwe-skin barrier, i-itch, ukusuleleka kunye neendawo ezinzima, ezinobunzima besikhumba. .8

Phakathi kwezigulane ezithatha i-lebrikizumab kunye ne-TCS, i-41 ipesenti iphumelele isikhumba esicacileyo okanye esicacileyo (IGA) kwiiveki ze-16 xa kuthelekiswa neepesenti ze-22 zezigulane ezithatha indawo ye-placebo kunye ne-TCS. Kwiiveki ze-16, i-70 yepesenti yezigulane ezithatha i-lebrikizumab kunye ne-TCS iphumelele impendulo ye-EASI-75 xa kuthelekiswa neepesenti ze-42 ezithatha indawo ye-placebo kunye ne-TCS. Umahluko phakathi kwezigulane ezifumana i-lebrikizumab ngokudibanisa ne-TCS kunye ne-placebo ene-TCS zibonwe kwangoko kwiiveki ezine ze-EASI-75.

Izigulana eziphathwe nge-lebrikizumab kunye ne-TCS ziphinde zafumana uphuculo olubalulekileyo lwezibalo kuzo zonke iziphelo eziphambili ezibandakanya ukucocwa kwesikhumba kunye nokurhawuzelelwa, ukuphazamiseka kwe-itch ebuthongweni, kunye nomgangatho wemilinganiselo yobomi, xa kuthelekiswa ne-placebo ene-TCS. Umahluko onentsingiselo ngokweklinikhi wabonwa kwangoko kwiiveki ezine zokurhawuzelelwa, ukuphazamiseka kokurhawuzelelwa ebuthongweni, kunye nomgangatho wemilinganiselo yobomi.

Iziphumo zokhuseleko zazihambelana nezifundo zangaphambili ze-lebrikizumab kwi-AD. Izigulane ezithatha i-lebrikizumab kunye ne-TCS, xa kuthelekiswa ne-placebo kunye ne-TCS, zichaze i-frequency ephezulu yeziganeko ezimbi (i-lebrikizumab kunye ne-TCS: i-43%, i-placebo kunye ne-TCS: 35%). Uninzi lweziganeko ezimbi zazincinci okanye zimodareyitha ngobunzima kwaye zingenangqondo kwaye azizange zikhokele ekuyekisweni konyango. Iziganeko ezibi kakhulu ze-lebrikizumab zaziyi-conjunctivitis (5%) kunye nentloko (5%).

"ULilly usebenza ukuxhobisa abantu abanezifo ezinxulumene nolusu, ezifana ne-atopic dermatitis, ukuba baphile ubomi babo ngokusemandleni," utshilo uLotus Mallbris, MD, Ph.D., usekela-mongameli wehlabathi jikelele wophuhliso lwe-immunology kunye nemicimbi yezonyango eLilly. . “Siyayibona imfuneko ebalulekileyo yokhetho olungakumbi kubantu abanesifo esingenakulawulwa ngemixholo. Sijonge phambili ekuboneni iziphumo ezipheleleyo ezivela kwinkqubo yethu yeSigaba sesi-3 esibanzi kunye nokuqhubela phambili i-lebrikizumab kwihlabathi liphela.

U-Lilly usandul 'ukwazisa idatha ye-16 yeeveki ezivela kwizifundo ze-ADvocate eziqhubekayo, kwaye inkcazo ekhonjiweyo yeziphumo iboniswe kwi-RAD 2022. Ukongezelela, idatha yexesha elide evela kwizifundo ze-ADvocate iya kuchazwa kwiinyanga ezizayo.

“Ezi ziphumo linyathelo elongezelelweyo ekuzibopheleleni kwethu ekuhambiseni amayeza amatsha okwenza umahluko onentsingiselo kwizigulana. Sijonge phambili ekubhengezeni amanyathelo amatsha anika umdla kwiinyanga ezizayo,” utshilo uKarl Ziegelbauer, Ph.D., iGosa eliyiNtloko lezeNzululwazi lase-Almirall SA.

U-Lilly unamalungelo akhethekileyo ophuhliso kunye norhwebo lwe-lebrikizumab e-United States kunye nehlabathi liphela ngaphandle kweYurophu. I-Almirall inike imvume yamalungelo okuphuhlisa kunye nokuthengisa i-lebrikizumab kunyango lwezibonakaliso zedermatology, kuquka i-AD, eYurophu.